Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in diabetic patients with non-alcoholic steatohepatitis
IRCT20210609051526N2Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Empagliflozin plus standard diabetes treatment with Placebo plus standard diabetes treatment (2 arms). Primary endpoints: Aspartate transaminase, Alanine transaminase and 1 more. Started Sep 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on IRCT20210609051526N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210609051526N2.